Intellia Therapeutics, Inc (NTLA) — 分析摘要
Intellia Therapeutics, Inc（NTLA）的市值为1.82十亿美元，最近一年的营收同比增长了+16.9%。净利润率为-609.9%。当前市盈率为-4.6倍。
核心要点
- 营收同比变化+16.9%
- 净利润率-609.9%
- 市盈率-4.6倍
与IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES板块的其他公司相比，NTLA的营收增长为+16.9%，市盈率为-4.6倍。
Intellia Therapeutics, Inc (NTLA)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -636.6% — 严重经营亏损
净利率为 -597.0% — 亏损超过收入（可能含一次性费用）
最新报表显示自由现金流为负。
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
行业
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
员工人数
377
总部
CAMBRIDGE, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。